David Liu, MD, MPH, MS

David Liu, MD, MPH, MS

Medical Oncology

Contact Information

Office Phone Number




Assistant Professor of Medicine, Harvard Medical School


Clinical Interests

Immuno-oncology, Melanoma, Predictive Biomarkers

Diseases Treated

Board Certification

  • Internal Medicine, 2015
  • Medical Oncology, 2019


  • DFCI and Harvard Cancer Care, Hematology/Oncology


  • Johns Hopkins Hospital, Internal Medicine

Medical School

  • Johns Hopkins University School of Medicine

Recent Awards

  • Damon-Runyon Physician-Scientist Training Grantee
  • ASCO Young Investigator Award
  • Society for Immunotherapy of Cancers-BMS Immunotherapy Translational Fellowship
  • AACR NextGen Stars


    Developing Computational Approaches to Dissecting Predictors of Therapeutic Response and Resistance

    The Liu lab operates at the intersection of clinical oncology, molecular biology, and computational biology, developing computational approaches to dissect therapeutic resistance and susceptibility to chemo-, targeted-, and immuno-therapies in patient tumors. Two broad areas of inquiry exist in the lab:

    1. Development of parsimonious predictive models utilizing statistical and machine learning approaches and integrating clinical and molecular data to guide clinical management.
    2. Mapping of clinical tumor heterogeneity and evolution of resistance and metastasis, using longitudinally collected tumor samples from patients over time, treatments, development of resistance, and from different metastatic sites to develop insight into drivers of resistance and metastasis.


      • STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming. Nat Commun. 2022 04 06; 13(1):1859. View in: Pubmed

      • Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. Nat Cancer. 2021 10; 2(10):1102-1112. View in: Pubmed

      • Biologically informed deep neural network for prostate cancer discovery. Nature. 2021 10; 598(7880):348-352. View in: Pubmed

      • Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun. 2021 09 21; 12(1):5563. View in: Pubmed

      • Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival. Cancer Res. 2021 08 01; 81(15):3971-3984. View in: Pubmed

      • Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med. 2021 06; 27(6):985-992. View in: Pubmed

      • Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med. 2021 03; 27(3):426-433. View in: Pubmed

      • Integrated molecular drivers coordinate biological and clinical states in melanoma. Nat Genet. 2020 12; 52(12):1373-1383. View in: Pubmed

      • Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. Clin Cancer Res. 2021 04 01; 27(7):2011-2022. View in: Pubmed

      • Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. J Clin Invest. 2020 08 03; 130(8):4266-4281. View in: Pubmed

      • Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discov. 2020 09; 10(9):1296-1311. View in: Pubmed

      • ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Res. 2020 06 01; 80(11):2094-2100. View in: Pubmed

      • Identification of cancer driver genes based on nucleotide context. Nat Genet. 2020 02; 52(2):208-218. View in: Pubmed

      • Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019 12; 25(12):1916-1927. View in: Pubmed

      • CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Rep. 2019 11 19; 29(8):2355-2370.e6. View in: Pubmed

      • Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3. View in: Pubmed

      • Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clin Cancer Res. 2019 09 15; 25(18):5561-5571. View in: Pubmed

      • Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer. Cancer Immunol Res. 2019 08; 7(8):1230-1236. View in: Pubmed

      • Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411. View in: Pubmed

      • Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. Am J Hematol. 2019 05; 94(5):E146-E149. View in: Pubmed

      • Mechanisms of Resistance to Immune Checkpoint Blockade. Am J Clin Dermatol. 2019 Feb; 20(1):41-54. View in: Pubmed

      • Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 11 01; 128(11):5185. View in: Pubmed

      • A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24. View in: Pubmed

      • Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 10 01; 128(10):4441-4453. View in: Pubmed

      • Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281. View in: Pubmed

      • ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2019 02 01; 25(3):977-988. View in: Pubmed

      • Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018 04 05; 173(2):321-337.e10. View in: Pubmed

      • The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018 05; 50(5):645-651. View in: Pubmed

      • Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. Cancer Discov. 2018 04; 8(4):417-427. View in: Pubmed

      • Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017 12 19; 8(1):2193. View in: Pubmed

      • Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2017; 1. View in: Pubmed

      • Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma. Cancer Discov. 2017 06; 7(6):555-557. View in: Pubmed

      • Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016 Aug 01; 2(8):1094-6. View in: Pubmed

      • The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med. 2016 07 26; 8(1):79. View in: Pubmed


      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Ave Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Ave Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      David Liu, MD, MPH, MS

      About Our Ratings

      Physician Star Rating Comment Block